Search

Search Constraints

You searched for: Author/Creator Morigi, Alice

Search Results

1. 90Y‐ibritumomab tiuxetan in patients with extra‐nodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) — The Zeno Study. (13th January 2020)

2. 90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years. (14th March 2016)

3. A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. Issue 2 (30th January 2019)

4. Bendamustine‐rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. Issue 4 (29th July 2020)

5. Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Issue 1 (15th October 2021)

6. Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma. (2nd September 2020)

7. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. (2nd August 2016)

8. Long‐Term Responders After Brentuximab Vedotin: Single‐Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. (2nd August 2016)

9. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real‐life experience. Issue 5 (30th September 2020)

10. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series. Issue 2 (April 2023)